Skip to main content

Rosetta Issued Notice of Allowance on miRNA Used in Cancer Diagnostic

Premium

Rosetta Genomics said this week that it has received a notice of allowance for a US patent application related to a microRNA used in its cancer of unknown primary origin diagnostic.

The application, No. 20080182237, is entitled "Lung Cancer-Related Nucleic Acids," and claims miRNAs, miRNA precursors, and associated nucleic acids associated with lung cancer for the prognosis, diagnosis, and treatment of the disease.

According to Rosetta, it covers miR-451, which is used in its miRview Mets test that is designed to determine the source of cancers of unknown primary origin.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.